- 01Positive is a lab cutoff, not a diagnosis
The word positive only means your lab's first dilution step lit up. At 1:160, about 1 in 20 healthy people still test positive 1, and many people with a positive result and no symptoms never develop autoimmune disease. Titer, pattern and symptoms together decide whether anything follows, and your clinician puts these together.
If your portal says "ANA positive, 1:160, speckled", you are in large company: millions of healthy people carry some antinuclear antibody, and a result like this is common without disease. What it means for you depends on your symptoms and your clinician's assessment, and if the test was ordered because of symptoms, the result needs that clinician's interpretation. ANA (antinuclear antibody) is an antibody that sticks to the nucleus of your own cells. A positive ANA does not diagnose lupus or anything else. Its meaning comes from three things: the titer (how far your blood can be diluted and still show the antibody), the pattern it makes under the microscope, and whether you have symptoms.
A sensitive screen like ANA is most useful when it is negative; a specific confirmer like anti-CCP, anti-dsDNA or tTG-IgA is most useful when it is positive.
ANA is a screening test for people whose symptoms suggest autoimmune disease: it is built to catch nearly every case, at the cost of flagging many people who are fine. It is not meant for people without symptoms. The hub page on <a href="/learn/autoimmune-antibodies-explained">autoimmune antibodies</a> explains screens and confirmers in full. For coeliac disease the confirmer is <a href="/biomarkers/ttg-iga">tTG-IgA</a>, and ANA plays no role. This page covers what an ANA result says by itself.
What the ANA titer means
The lab dilutes your serum (the liquid part of blood) step by step and checks at each step whether antibody still binds to a layer of HEp-2 cells (a lab-grown line of human cells with large nuclei) on a slide. The titer is the last dilution where the cells still glow under a fluorescence microscope. A result of 1:160 means the antibody was still visible after your serum was diluted 160-fold. Higher second numbers mean more antibody.
Positive results become much rarer as the titer climbs. In the multicenter study by Tan and colleagues, which ran samples from healthy people through 15 international labs, the share testing positive fell by more than half with each early step up the ladder 1.
US population data tell the same story. In the NHANES survey (1999 to 2004, ages 12 and up), 13.8% of Americans were ANA positive at 1:80 or higher, about 32 million people. Positivity was 17.8% in women and 9.6% in men, and it rose with age 2. A positive ANA in a woman over 50 with no symptoms is a common finding.
Where an example titer of 1:160 fallstiter (1:x)
| ANA titer | Healthy people positive at this titer | How the result usually reads |
|---|---|---|
| Negative (below 1:40 or 1:80, by lab) | Most healthy people | Makes lupus very unlikely, though not impossible; ANA is positive at 1:80 or higher in about 98% of people with lupus 3 |
| 1:40 | 31.7% 1 | Low positive; common without disease |
| 1:80 | 13.3% 1 | Low positive; meets the entry point of the lupus classification criteria but means little without symptoms 3 |
| 1:160 | 5.0% 1 | Borderline; meaning depends on symptoms and pattern |
| 1:320 | 3.3% 1 | Moderate; more likely to prompt follow-up testing if symptoms are present |
| 1:640 and above | Uncommon in healthy people | High; a rheumatologist usually orders targeted antibody tests, especially with symptoms |
There is no separate "optimal" ANA. The best result is negative, and the lab's reference range marks where it starts calling a result positive. The page on <a href="/learn/reference-ranges-explained">reference ranges</a> explains why screening cutoffs are set low enough to accept some false positives.
What ANA patterns mean
The pattern describes where in the cell nucleus the glow appears. Since 2015 the International Consensus on ANA Patterns (ICAP) has given each pattern a code from AC-0 upward, so labs can describe the same image the same way 4. Patterns hint at which antibody is present; they do not diagnose a disease.
| Pattern (ICAP code) | What the lab sees | Often linked with (not diagnostic) |
|---|---|---|
| Homogeneous (AC-1) | Even glow across the whole nucleus | Antibodies to DNA and histones (proteins DNA wraps around); lupus and drug-induced lupus, also healthy people |
| Dense fine speckled (AC-2) | Fine, uneven speckles across the nucleus | Anti-DFS70 (an antibody common in healthy people); seen far more often in healthy people than in systemic autoimmune disease 4 |
| Centromere (AC-3) | 40 to 80 distinct dots in the nucleus | Limited systemic sclerosis (scleroderma, a disease that thickens skin and can affect organs) and primary biliary cholangitis (a slow autoimmune disease of the small bile ducts in the liver) |
| Speckled, fine or coarse (AC-4, AC-5) | Grainy speckles | Antibodies such as SSA/Ro, SSB/La, Sm and RNP; Sjögren's disease, lupus, mixed connective tissue disease (an overlap of features of lupus, scleroderma and muscle inflammation) |
| Nucleolar (AC-8 to AC-10) | Glow inside the nucleoli (small dense spots in the nucleus) | Systemic sclerosis and some overlap conditions |
Speckled is the pattern labs report most often, and it points to many different antibodies. A dense fine speckled (AC-2) pattern at low titer, with no symptoms, is one of the most reassuring positive ANA results a person can get 4. If your report just says "speckled", ask the lab or your clinician whether it is dense fine speckled (AC-2); some labs can run an anti-DFS70 test to confirm it.
Why the test method matters
Titers and patterns only come from immunofluorescence on HEp-2 cells (abbreviated IIF), the method ICAP is built on 4. The American College of Rheumatology calls HEp-2 IIF the gold standard and says labs that screen with automated bead or ELISA assays (automated tests that detect antibody with a colour reaction) should be able to provide an IIF result on request 6. If your report says only "positive" with no titer or pattern, it may have come from an automated screen, and your clinician can ask whether the lab can run IIF.
Follow-up tests after a positive ANA
When the ANA is positive and symptoms point toward an autoimmune disease, the next tests target specific antibodies. The American College of Rheumatology advises against ordering these targeted tests before a positive ANA and a clinical reason:
Don't test ANA sub-serologies without a positive ANA and clinical suspicion of immune-mediated disease.American College of Rheumatology, Choosing Wisely list, 2013 5
Sub-serologies are the specific follow-up antibody tests listed below.
| Follow-up test | What it looks for | When a rheumatologist may order it |
|---|---|---|
| <a href="/biomarkers/anti-dsdna">Anti-dsDNA</a> | Antibody to double-stranded DNA; highly specific for lupus and scored in the 2019 criteria 3 | Positive ANA (often homogeneous) plus symptoms suggesting lupus |
| Anti-Sm | Antibody to the Smith antigen; highly specific for lupus 3 | Same situation as anti-dsDNA, usually ordered together in an ENA (extractable nuclear antigen) panel |
| <a href="/biomarkers/anti-ssa-ssb">Anti-SSA/Ro and anti-SSB/La</a> | Antibodies linked with Sjögren's disease and lupus | Dry eyes and mouth, speckled pattern, or before pregnancy in someone with known autoimmune disease |
| <a href="/biomarkers/complement-c3">Complement C3</a> and <a href="/biomarkers/complement-c4">C4</a> | Immune proteins that get used up when lupus is active; low C3 or C4 scores in the 2019 criteria 3 | Suspected or known lupus, often repeated to track activity |
| Anti-centromere, anti-Scl-70 | Antibodies linked with systemic sclerosis | Centromere or nucleolar pattern, fingers that turn white or blue in the cold (Raynaud's), skin thickening |
Alongside the antibody tests, your clinician will usually order a <a href="/learn/cbc-explained">complete blood count</a> (lupus can lower white cells or platelets) and a <a href="/learn/urinalysis-explained">urine test</a> to check the kidneys.
If the question is rheumatoid arthritis rather than lupus, the relevant tests are <a href="/biomarkers/rheumatoid-factor">rheumatoid factor</a> and <a href="/biomarkers/anti-ccp">anti-CCP</a>, not ANA. Inflammation markers such as CRP and ESR measure general inflammation and are covered in <a href="/learn/inflammation-markers-explained">inflammation markers explained</a>.
Other reasons an ANA comes back positive
- Age and sex: ANA positivity rises with age and is nearly twice as common in women as in men 2.
- Autoimmune thyroid disease: a positive ANA often appears alongside Hashimoto's thyroiditis, the most common cause of <a href="/conditions/hypothyroidism">hypothyroidism</a>. The <a href="/learn/how-to-read-your-thyroid-panel">thyroid panel guide</a> explains TSH and thyroid antibodies.
- Certain medicines, such as hydralazine, procainamide and some TNF-blocking drugs (injected or infused medicines for rheumatoid arthritis, psoriasis or Crohn's disease), can raise ANA and occasionally cause drug-induced lupus. Never stop a prescribed medicine on your own; raise it with the prescriber.
- Recent infections and some liver and lung conditions can produce a positive ANA; the <a href="/learn/liver-enzymes-explained">liver enzymes guide</a> covers the liver tests your clinician may check.
Antibodies can appear before symptoms in some people who later develop lupus. The hub page puts the timing this way:
Autoantibodies can show up years before symptoms: in one US military cohort, lupus antibodies appeared a mean of about 3.3 years before diagnosis (Arbuckle et al., 2003).
Most people with a positive ANA never develop lupus, because the antibody is so common in healthy people 1 2. For a symptom-free person with a positive ANA, the useful step is knowing which symptoms to report.
Testing practicalities
- Fasting: none needed. ANA is a standard blood draw.
- Ordering: ANA is a separate order and is not part of a routine checkup, metabolic panel or CBC. It is usually ordered because of symptoms, and insurance coverage generally depends on there being a clinical reason. Prices vary by lab and plan.
- Screening: guidelines do not recommend ANA as a screening test for people without symptoms, because low positives are so common in healthy people 1 5. If you have a relative with lupus, discuss with your clinician whether testing makes sense for you.
- Retesting: once an ANA is positive, repeating it rarely changes anything; rheumatology guidance advises against repeating a confirmed positive ANA in people with established lupus 5. Doctors follow anti-dsDNA and complement instead. This is one of the few markers where the advice in <a href="/learn/trends-beat-single-readings">trends beat single readings</a> does not apply.
- Can it turn negative? Titers can drift up or down, and a low positive sometimes reads negative on a repeat test or at a different lab. A one-step change, such as between 1:80 and 1:160, is generally considered within test-to-test variation, so ask your clinician before reading meaning into it.
For more on autoimmune tests and conditions, see the <a href="/topics/autoimmune">autoimmune topic hub</a>. New to lab reports? Start with <a href="/learn/how-to-read-any-lab-result">how to read any lab result</a>. A rheumatologist is the right person to interpret a positive ANA alongside your symptoms and examination.
This page is educational information, not medical advice or a diagnosis, and it cannot tell you what your own result means. Only a clinician who knows your symptoms, examination and history can interpret your result and decide on next steps.
Citations
- Tan EM et al. Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum. 1997;40(9):1601-11
- Satoh M et al. Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. Arthritis Rheum. 2012;64(7):2319-27
- Aringer M et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol. 2019;71(9):1400-12
- Chan EKL et al. Report of the First International Consensus on Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns (ICAP) 2014-2015. Front Immunol. 2015;6:412
- American College of Rheumatology. Choosing Wisely: Five Things Physicians and Patients Should Question (adult rheumatology list, 2013; pediatric rheumatology list, 2014: "Don't repeat a confirmed positive ANA in patients with established JIA or SLE")
- Meroni PL, Schur PH. ANA screening: an old test with new recommendations. Ann Rheum Dis. 2010;69(8):1420-2 (summarising the American College of Rheumatology position statement on ANA testing methodology)
- Arbuckle MR et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349(16):1526-33
Educational context only, not medical advice or a diagnosis. Always discuss your results with a clinician.